TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28292532

Group type: EXPERIMENTAL
Intervention: Intravenous iron therapy (200mg Venofer® diluted in 100ml saline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (100ml saline)
Number of subjects: 0
Study: 25774878

Group type: EXPERIMENTAL
Intervention: Computer self-administration of the CRAFFT screening protocol
Number of subjects: 136

Group type: COMPARATOR
Intervention: Clinician-administration of the CRAFFT screening protocol
Number of subjects: 136
Study: 25343657

Group type: EXPERIMENTAL
Intervention: Medically assisted detoxification
Number of subjects: 262

Group type: COMPARATOR
Intervention: No medically assisted detoxification
Number of subjects: 262
Study: 23001955

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injection (RLAI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol decanoate depot
Number of subjects: 0
Study: 19508532

Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy (SH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rubber band ligation (RBL)
Number of subjects: 60
Study: 17870260

Group type: EXPERIMENTAL
Intervention: tibolone 1.25mg/day
Number of subjects: 308

Group type: COMPARATOR
Intervention: raloxifene 60 mg/day
Number of subjects: 308
Study: 15927965

Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing for fast ventricular tachycardia (FVT)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Shock for fast ventricular tachycardia (FVT)
Number of subjects: 582
Study: 12437455

Group type: EXPERIMENTAL
Intervention: 0.1% tazarotene cream
Number of subjects: 563

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 563
Study: 10481500

Group type: EXPERIMENTAL
Intervention: Histamine effect on T lymphocytes in patients with seasonal allergic rhinitis
Number of subjects: 240

Group type: COMPARATOR
Intervention: Allergic skin tests, serum level of IgE, Multitest CMI, percentage of lymphocytes T (CD3), percentage of lymphocytes T helper (CD4), percentage of lymphocytes T cytotoxic (CD8)
Number of subjects: 240
Study: 8623802

Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 40
Study: 1946889

Group type: EXPERIMENTAL
Intervention: Active behavioral task (32 subjects)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (9 subjects)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (10 subjects)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (15 subjects)
Number of subjects: 96
Study: 7116662

Group type: EXPERIMENTAL
Intervention: Active regimen (hydrochlorothiazide‐triamterene with or without methyldopa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29147968

Group type: EXPERIMENTAL
Intervention: Fasting for 35 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fasting for 5 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fasting for 7 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fasting for 14 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fasting for 1 day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Prolonged fasting
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 35
Study: 27659392

Group type: EXPERIMENTAL
Intervention: Dementia education program delivered to intervention group (IG)
Number of subjects: 745

Group type: COMPARATOR
Intervention: Wait-listed group (control)
Number of subjects: 745
Study: 24879975

Group type: EXPERIMENTAL
Intervention: Inotropes used in patients with SBP <100 mm Hg (53.3% of 165 patients)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Inotropes used in patients with SBP ≥100 mm Hg (40.5% of 262 patients)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Inotropes used in patients with cardiac index ≥1.8 L min(‐1) m(‐2) (n = 114)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Inotropes used in patients with cardiac index <1.8 L min(‐1) m(‐2) (n = 82)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Inotropes used in ischemic patients (n = 215)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Inotropes used in nonischemic patients (n = 216)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Inotropes used in all subgroups
Number of subjects: 427
Study: 23859257

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 3 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 6 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (obese nonapneic matched controls)
Number of subjects: 100
Study: 20579357

Group type: EXPERIMENTAL
Intervention: Structured lifestyle program (diet, increased physical activity, and behavioral modification) aiming for 5%-10% weight loss over six months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional fertility care only (control group).
Number of subjects: 0
Study: 19137767

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 1373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1373
Study: 16365119

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 20
Study: 14576501

Group type: EXPERIMENTAL
Intervention: Meropenem 0.5 g t.i.d. intravenously
Number of subjects: 176

Group type: COMPARATOR
Intervention: Imipenem 0.5 g q.i.d. intravenously
Number of subjects: 176
Study: 10756289

Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue graft
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Free full-thickness gingival graft
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (unoperated defects)
Number of subjects: 24
Study: 9133860

Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate and lidocaine hydrochloride
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lidocaine hydrochloride
Number of subjects: 27

Group type: COMPARATOR
Intervention: pH-buffered saline (placebo)
Number of subjects: 27
Study: 1345218

Group type: EXPERIMENTAL
Intervention: atenolol 50 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: co‐amiloride 25 mg + amiloride 5 mg once daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 100
Study: 3909456

Group type: EXPERIMENTAL
Intervention: Metronidazole (Flagyl; Maybaker)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tinidazole (Fasigyn; Pfizer)
Number of subjects: 48
Study: 31860104

Group type: EXPERIMENTAL
Intervention: STAT-ED intervention (motivational interviewing)
Number of subjects: 168

Group type: COMPARATOR
Intervention: EUC (enhanced usual care)
Number of subjects: 168
Study: 29414827

Group type: EXPERIMENTAL
Intervention: Statins at baseline
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: No statins at baseline
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study: 27288618

Group type: EXPERIMENTAL
Intervention: Inhaled sodium heparin (5000 units in 2 mL) nebulization four times daily
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Inhaled sodium chloride (0.9% sodium chloride, 2 mL) nebulization four times daily
Number of subjects: 214
Study: 26184173

Group type: EXPERIMENTAL
Intervention: Combined workout group (CWG) - combined endurance/resistance workout (20 min on a bicycle ergometer, followed by 20 min of resistance training)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Endurance workout group (EWG) - 40 min endurance training program
Number of subjects: 28
Study: 21632438

Group type: EXPERIMENTAL
Intervention: Distressing high-resolution color images
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less distressing two-color images with degraded outline and detail
Number of subjects: 0
Study: 20646373

Group type: EXPERIMENTAL
Intervention: Ultrasonic dissector (UAS)
Number of subjects: 2736

Group type: COMPARATOR
Intervention: Conventional technique (CT)
Number of subjects: 2736
Study: 18818847

Group type: EXPERIMENTAL
Intervention: In-shower body lotion product form
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control exposure method
Number of subjects: 0
Study: 15956130

Group type: COMPARATOR
Intervention: 0 Gy (placebo)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 7 Gy
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 10.5 Gy
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 14 Gy
Number of subjects: 99
Study: 11834994

Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unreamed intramedullary nailing
Number of subjects: 20
Study: 10369587

Group type: EXPERIMENTAL
Intervention: Relative lens-sparing (RLS) technique
Number of subjects: 42

Group type: COMPARATOR
Intervention: Modified lateral beam (MLB) technique
Number of subjects: 42
Study: 7595716

Group type: EXPERIMENTAL
Intervention: GM‐CSF 4 micrograms/kg subcutaneously from days 5 to 14
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GM‐CSF in the second cycle of PFL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GM‐CSF treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 20
Study: 2073486

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% with epinephrine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Bupivacaine 0.75% with epinephrine
Number of subjects: 43
Study: 728485

Group type: EXPERIMENTAL
Intervention: Contingent feedback (CF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noncontingent (yoked) feedback (YF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No feedback (NF)
Number of subjects: 0
Study: 31950267

Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S) at 0.5, 1.0, and 1.5 MAC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propofol (group P) at Ce of 4 μg/ml
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propofol (group P) at Ce of 2 or 3 μg/ml
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sevoflurane and Propofol at clinical concentrations
Number of subjects: 24
Study: 31097405

Group type: EXPERIMENTAL
Intervention: Pomalidomide, bortezomib, and dexamethasone
Number of subjects: 559

Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone
Number of subjects: 559
Study: 27346437

Group type: EXPERIMENTAL
Intervention: Irbesartan 150-300 mg/day
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 26447156

Group type: EXPERIMENTAL
Intervention: Choline supplementation (500 mg daily for 9 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23517797

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (target HbA1c < 6.5%)
Number of subjects: 23182

Group type: COMPARATOR
Intervention: Conventional glycemic control (target HbA1c > 6.4%)
Number of subjects: 23182
Study: 18317601

Group type: EXPERIMENTAL
Intervention: Endotracheal tube cuffs filled with alkalinized lidocaine (2% lidocaine plus 8.4% sodium bicarbonate)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Endotracheal tube cuffs filled with air
Number of subjects: 50
Study: 15330679

Group type: EXPERIMENTAL
Intervention: Estradiol/levonorgestrel (4.4/2.74 and 4.5/3.75mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estradiol/levonorgestrel (4.4/1.39 [approved dosage], 4.4/2.74, and 4.5/3.75mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estradiol/levonorgestrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estradiol/levonorgestrel (4.4/1.39mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estradiol/levonorgestrel and estradiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estradiol/levonorgestrel, estradiol, and placebo
Number of subjects: 0
Study: 11130523

Group type: COMPARATOR
Intervention: ACE inhibitors (placebo-controlled trials)
Number of subjects: 12352

Group type: COMPARATOR
Intervention: Calcium antagonists (placebo-controlled trials)
Number of subjects: 12352

Group type: EXPERIMENTAL
Intervention: More intensive blood-pressure-lowering strategies
Number of subjects: 12352

Group type: EXPERIMENTAL
Intervention: Calcium-antagonist-based therapy
Number of subjects: 12352
Study: 9491722

Group type: EXPERIMENTAL
Intervention: Doxazosin (Cardura)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8255408

Group type: EXPERIMENTAL
Intervention: 10 mg of the partial 5‐HT1A agonist ipsapirone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exposure to cold ambient temperature (5 degrees C) and placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exposure to normal ambient temperature (28 degrees C) and placebo
Number of subjects: 60
Study: 2862819

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30019249

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Minodronate (1 mg/day or 50 mg/4 weeks)
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1734
Study: 29099521

Group type: EXPERIMENTAL
Intervention: 25 g FDSP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 50 g FDSP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 26518728

Group type: EXPERIMENTAL
Intervention: Nicotine administration
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 2
Study: 25079979

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS over the primary motor cortex of the lower leg (M1-LL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS over the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 22270787

Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR) analysis
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Five breast radiologists
Number of subjects: 140
Study: 19566902

Group type: EXPERIMENTAL
Intervention: Botulinum toxin serotype B (BoNT/B) injections into the masseter muscles
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study: 17350783

Group type: EXPERIMENTAL
Intervention: Standard information and a newly written extended information brochure about risks in connection with cardiac surgery (Intervention group)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard information (Control group)
Number of subjects: 99
Study: 15357646

Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a 12 MIU (44 microg) administered three times weekly
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a 24 MIU (88 microg) administered three times weekly
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a 12 MIU (44 microg) administered daily
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a 24 MIU (88 microg) administered daily
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a in Chinese patients
Number of subjects: 267
Study: 11248171

Group type: EXPERIMENTAL
Intervention: Stapled grafts
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sewn grafts
Number of subjects: 84
Study: 9833848

Group type: EXPERIMENTAL
Intervention: Abacavir monotherapy (200, 400, or 600 mg every 8 h daily, or 300 mg every 12 h daily)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Abacavir-ZDV combination therapy (600 mg ZDV)
Number of subjects: 79
Study: 7805984

Group type: EXPERIMENTAL
Intervention: 2% testosterone propionate
Number of subjects: 58

Group type: COMPARATOR
Intervention: Petrolatum ointment
Number of subjects: 58
Study: 2633019

Group type: EXPERIMENTAL
Intervention: Oral tramadol 100 mg and lorazepam 1 mg (Group A)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Flunitrazepam 1 mg (Group B)
Number of subjects: 200
Study: 241602

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Alclofenac
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31662118

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 433
Study: 31342566

Group type: EXPERIMENTAL
Intervention: 25 mg of lingonberry extract and 30 mg of amla fruit extract
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 50 mg of lingonberry extract and 60 mg of amla fruit extract
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 99
Study: 28065436

Group type: EXPERIMENTAL
Intervention: SE-PMMA IOL
Number of subjects: 94
Study: 25375836

Group type: EXPERIMENTAL
Intervention: Escitalopram (5-20 mg/d)
Number of subjects: 217
Study: 23815124

Group type: EXPERIMENTAL
Intervention: Nitroglycerin 0.4% ointment (375 mg applied anally every 12 hours for 21 days)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo ointment (375 mg applied anally every 12 hours for 21 days)
Number of subjects: 247
Study: 21774823

Group type: EXPERIMENTAL
Intervention: Seclusion (minimally furnished seclusion room with open but barred windows onto the nursing station)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical restraints (strong cotton banding to edge of bed with medications as indicated and close observation)
Number of subjects: 0
Study: 19789597

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone
Number of subjects: 10
Study: 16883264

Group type: EXPERIMENTAL
Intervention: Quinapril (Q) at an average dose of 13 mg/day (n=28)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Valsartan (V) at a dose of 121 mg/day (n=26)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of Quinapril and Valsartan (Q+V) at doses of 12 mg/day and 78 mg/day respectively (n=26)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Quinapril (Q)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Valsartan (V)
Number of subjects: 80
Study: 15054339

Group type: EXPERIMENTAL
Intervention: Strictly adherent (SA) group
Number of subjects: 163

Group type: COMPARATOR
Intervention: Not strictly adherent (NSA) group
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Both SA and NSA groups
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: SA subjects
Number of subjects: 163
Study: 11408125

Group type: EXPERIMENTAL
Intervention: PMMA intraocular lens (IOL) implantation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Silicone intraocular lens (IOL) implantation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Acrylic intraocular lens (IOL) implantation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Nd:YAG capsulotomy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Visual acuity
Number of subjects: 300
Study: 9240579

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation >8000 IU daily
Number of subjects: 1508

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation >10000 IU daily
Number of subjects: 1508

Group type: COMPARATOR
Intervention: Normal control group (consuming <5000 IU)
Number of subjects: 1508
Study: 8214491

Group type: EXPERIMENTAL
Intervention: Pre-operative terfenadine (60 mg) and ranitidine (150 mg) with intra-operative tubocurarine and morphine (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pre-operative placebo and intra-operative tubocurarine and morphine (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pre-operative placebo and intra-operative fentanyl and vecuronium (group C)
Number of subjects: 60
Study: 3623736

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg every 12 hours for 7 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nalidixic acid 500 mg every 8 hours for 7 days
Number of subjects: 72
Study: 30539861

Group type: EXPERIMENTAL
Intervention: Endostar continuous intravenous infusion combined with SOX regimen chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: SOX regimen chemotherapy alone
Number of subjects: 60
Study: 27525830

Group type: EXPERIMENTAL
Intervention: Moderate-intensity treadmill exercise
Number of subjects: 75

Group type: COMPARATOR
Intervention: Stretching and toning exercise (Control)
Number of subjects: 75
Study: 25026287

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: NPM1mut MRD
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: WT1 MRD
Number of subjects: 260
Study: 23040422

Group type: EXPERIMENTAL
Intervention: Screening followed by intensive multifactorial treatment for people diagnosed with diabetes (n=15)
Number of subjects: 20184

Group type: EXPERIMENTAL
Intervention: Screening plus routine care of diabetes according to national guidelines (n=13)
Number of subjects: 20184

Group type: COMPARATOR
Intervention: No screening (control group) (n=5)
Number of subjects: 20184

Group type: EXPERIMENTAL
Intervention: Screening (general)
Number of subjects: 20184
Study: 20542931

Group type: EXPERIMENTAL
Intervention: Individualised bladder rehabilitation programme (n=40)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control waitlist group (n=34)
Number of subjects: 74
Study: 18182412

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ampicillin plus gentamicin
Number of subjects: 0
Study: 15972025

Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 14
Study: 12563578

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerine (SL NTG) plus 1 mg of lorazepam intravenously (Group 2)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sublingual nitroglycerine (SL NTG) alone (Group 1)
Number of subjects: 27
Study: 11111384

Group type: COMPARATOR
Intervention: BVCM (bleomycin, vincristine, methotrexate, plus cisplatin)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BVM (bleomycin, vincristine, methotrexate)
Number of subjects: 38
Study: 9006788

Group type: EXPERIMENTAL
Intervention: Topical ibuprofen (ibugel, 3 x 375 mg daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oral ibuprofen (2 x 600 mg daily)
Number of subjects: 17
Study: 1298490

Group type: EXPERIMENTAL
Intervention: Warning stimulation paradigm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long, random, and self-triggered stimulation paradigms
Number of subjects: 0